These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31703356)

  • 1. WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage.
    de Jong MRW; Langendonk M; Reitsma B; Herbers P; Nijland M; Huls G; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31703356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Herbers P; Lodewijk M; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Ther Adv Hematol; 2020; 11():2040620719898373. PubMed ID: 32010435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
    Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells.
    Vera J; Raatz Y; Wolkenhauer O; Kottek T; Bhattacharya A; Simon JC; Kunz M
    Cell Signal; 2015 May; 27(5):951-60. PubMed ID: 25683911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
    Garcia TB; Fosmire SP; Porter CC
    Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax.
    Vervloessem T; Akl H; Tousseyn T; De Smedt H; Parys JB; Bultynck G
    Oncotarget; 2017 Dec; 8(67):111656-111671. PubMed ID: 29340082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition.
    Patel P; Sun L; Robbins Y; Clavijo PE; Friedman J; Silvin C; Van Waes C; Cook J; Mitchell J; Allen C
    Oncoimmunology; 2019; 8(11):e1638207. PubMed ID: 31646086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations.
    Meng X; Bi J; Li Y; Yang S; Zhang Y; Li M; Liu H; Li Y; Mcdonald ME; Thiel KW; Wen KK; Wang X; Wu M; Leslie KK
    Cancers (Basel); 2018 May; 10(5):. PubMed ID: 29783721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational status of
    Ku BM; Bae YH; Koh J; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Oncotarget; 2017 Sep; 8(40):67526-67537. PubMed ID: 28978051
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer.
    Wang Q; Chao Y; Chen Y; Zheng W; Demanelis K; Liu Y; Connelly J; Wang H
    Res Sq; 2023 Nov; ():. PubMed ID: 37987002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WEE1 inhibition and genomic instability in cancer.
    Vriend LE; De Witt Hamer PC; Van Noorden CJ; Würdinger T
    Biochim Biophys Acta; 2013 Dec; 1836(2):227-35. PubMed ID: 23727417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
    Bell HL; Blair HJ; Singh M; Moorman AV; Heidenreich O; van Delft FW; Lunec J; Irving JAE
    Cancer Cell Int; 2023 Sep; 23(1):202. PubMed ID: 37715172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.
    Wright G; Golubeva V; Remsing Rix LL; Berndt N; Luo Y; Ward GA; Gray JE; Schonbrunn E; Lawrence HR; Monteiro ANA; Rix U
    ACS Chem Biol; 2017 Jul; 12(7):1883-1892. PubMed ID: 28557434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.
    Geenen JJJ; Schellens JHM
    Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-induced differential cell cycle arrest in B-cell lymphomas affects their sensitivity to Wee1 inhibition.
    Wang X; Chen Z; Mishra AK; Silva A; Ren W; Pan Z; Wang JH
    Haematologica; 2018 Mar; 103(3):466-476. PubMed ID: 29217775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations.
    Serpico AF; D'Alterio G; Vetrei C; Della Monica R; Nardella L; Visconti R; Grieco D
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31200459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
    Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
    Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancer.
    Drainas AP; Hsu WH; Dallas AE; Poltorack CD; Kim JW; He A; Coles GL; Baron M; Bassik MC; Sage J
    Cell Rep; 2024 Aug; 43(8):114606. PubMed ID: 39120974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.